- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04004325
A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis
March 14, 2022 updated by: Forma Therapeutics, Inc.
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability and Efficacy of FT-4101 in Overweight/Obese Subjects With NASH
This Phase 1/2 study will evaluate safety, efficacy, PK, and PD of FT-4101 as a single agent in overweight/obese subjects with NASH.
The study may be conducted in up to 2 dosing cohorts.
Study Overview
Status
Terminated
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Chula Vista, California, United States, 91911
- ProSciento, Inc.
-
Montclair, California, United States, 91763
- Catalina Research Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
Meets all of the following criteria:
- CAP ≥ 300 dB/m by FibroScan® OR Liver biopsy within 24 months, consistent with NASH with stage 2-3 fibrosis
- Screening MRI-PDFF with ≥ 10% steatosis.
- Body mass index (BMI) > 25.0 to < 45.0 kg/m2
- Stable body weight
Subjects with T2DM may also be included, if:
- Subject with T2DM is on stable doses of metformin monotherapy (subjects on combination therapy of metformin and sulfonylurea (SU) need to undergo washout period prior to dosing) with no changes in medication within the previous 6 months
- HbA1c < 9% (one retest is permitted with the result of the last test being conclusive)
- Fasting plasma glucose (FPG) < 240 mg/dL (<13.3 mmol/L)
- Waist circumference ≤ 57 inches
- Female subjects must be non-pregnant and non-lactating
Key Exclusion Criteria:
- Type 1 diabetes and type 2 diabetic subjects on insulin therapy
- Diabetic complications, such as acute proliferative retinopathy
- Recurrent severe hypoglycemia or hypoglycemic unawareness or recent severe ketoacidosis
- History of, or active, chronic liver disease due to alcohol, auto-immune, primary biliary cholangitis, HIV, HBV or active HCV-infection, Wilson's, α-1-antitrypsin deficiency, hemochromatosis, etc., and not due to NASH disease
- History of clinically significant or decompensated chronic liver disease including esophageal varices, ascites, encephalopathy or any hospitalization for treatment of chronic liver disease; or MELD score ≥ 10.
- History of significant cirrhosis of the liver
- Alcohol consumption greater than 14 drinks per week for men or greater than 7 drinks per week for women and/or positive alcohol breath test
- Introduction of an anti-obesity drug in the past 6 months prior to screening
- History of gastrointestinal malabsorptive bariatric surgery, any other gastrointestinal surgery that may induce malabsorption, history of bowel resection > 20 cm, any malabsorption disorder, severe gastroparesis, any GI procedure for weight loss, as well as clinically significant gastrointestinal disorders within less than 5 years
- Ingestion of drugs known to produce hepatic steatosis including corticosteroids, high- dose estrogens, methotrexate, tetracycline or amiodarone in the previous 6 months
- History of, or current cardiac dysrhythmias and/or a history of cardiovascular disease events, including congestive heart failure, unstable coronary artery disease, myocardial infarction
- Significant systemic or major illnesses other than liver disease, including cerebrovascular disease, pulmonary disease, renal failure, organ transplantation, serious psychiatric disease, malignancy that, in the opinion of the investigator, would preclude treatment with FT-4101 and/or adequate follow up
- History of chronic skin conditions such as psoriasis, eczema or any recurring rash/dermatitis requiring oral or topical corticosteroids or other topical applications within 12 months
- Hair loss or unexplained alopecia within 12 months
- History of chronic eye conditions, Sjögren syndrome or any history of dry eyes or allergic conjunctivitis requiring artificial tears or medicated eye drops or previous refractive surgery within 12 months (Subjects with dry eyes due to wearing contact lenses are eligible)
- History of major depression, anxiety, suicidal behavior or attempts, or other unstable psychiatric disorders (within 2 years of screening), requiring medical treatment
- Uncontrolled hypertension
- Any device or other contraindication with the MRI examination
- Ingestion of deuterated water within the previous 6 months
- Positive test for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus type 1 (HIV-1) or type 2 (HIV-2) antibody
- Participation in any other clinical interventional study receiving active treatment within the previous 30 days or 5 half-lives, whichever is longer
- Unable to abstain from smoking during confinement periods
- History of illicit drug abuse
- Clinically under the effect of marijuana at screening
- Unwillingness to abstain from grapefruit (grapefruit containing food and beverages), star fruit (carambola), pomegranate, Seville orange and other food components that may interact with CYP3A4 from check-in throughout the entire course of the study
- Donation or loss of > 500 mL of blood or blood product within 56 days of dosing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort A
|
FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.
FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.
Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).
|
EXPERIMENTAL: Cohort B
|
FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.
FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.
Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse events
Time Frame: Participants to be followed for duration of participation, which is approximately 20 weeks
|
Participants to be followed for duration of participation, which is approximately 20 weeks
|
Incidence of clinical lab abnormalities
Time Frame: Participants to be followed for duration of participation, which is approximately 20 weeks
|
Participants to be followed for duration of participation, which is approximately 20 weeks
|
Change from baseline in vital signs (blood pressure [BP]: mmHg)
Time Frame: Participants to be followed for duration of participation, which is approximately 20 weeks
|
Participants to be followed for duration of participation, which is approximately 20 weeks
|
Change from baseline in vital signs (heart rate [HR]: beats/min)
Time Frame: Participants to be followed for duration of participation, which is approximately 20 weeks
|
Participants to be followed for duration of participation, which is approximately 20 weeks
|
Change from baseline in vital signs (respiratory rate [RR]: breaths/min)
Time Frame: Participants to be followed for duration of participation, which is approximately 20 weeks
|
Participants to be followed for duration of participation, which is approximately 20 weeks
|
Change from baseline in vital signs (temperature [aural]: degrees Celsius)
Time Frame: Participants to be followed for duration of participation, which is approximately 20 weeks
|
Participants to be followed for duration of participation, which is approximately 20 weeks
|
Change from baseline in 12-lead electrocardiogram (ECG) parameters (heart rate [HR]: beats/min)
Time Frame: Participants to be followed for duration of participation, which is approximately 20 weeks
|
Participants to be followed for duration of participation, which is approximately 20 weeks
|
Change from baseline in 12-lead electrocardiogram (ECG) parameters (QT interval: milliseconds)
Time Frame: Participants to be followed for duration of participation, which is approximately 20 weeks
|
Participants to be followed for duration of participation, which is approximately 20 weeks
|
Change from baseline in 12-lead electrocardiogram (ECG) parameters (PR interval: milliseconds)
Time Frame: Participants to be followed for duration of participation, which is approximately 20 weeks
|
Participants to be followed for duration of participation, which is approximately 20 weeks
|
Change from baseline in 12-lead electrocardiogram (ECG) parameters (QRS interval: milliseconds)
Time Frame: Participants to be followed for duration of participation, which is approximately 20 weeks
|
Participants to be followed for duration of participation, which is approximately 20 weeks
|
Change from baseline in 12-lead electrocardiogram (ECG) parameters (RR interval: milliseconds)
Time Frame: Participants to be followed for duration of participation, which is approximately 20 weeks
|
Participants to be followed for duration of participation, which is approximately 20 weeks
|
Change from baseline in 12-lead electrocardiogram (ECG) parameters (QTcF interval: milliseconds)
Time Frame: Participants to be followed for duration of participation, which is approximately 20 weeks
|
Participants to be followed for duration of participation, which is approximately 20 weeks
|
Reduction (absolute and relative) of % liver fat on MRI-PDFF
Time Frame: Assessed at 12 weeks
|
Assessed at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reduction (absolute and relative) of % liver fat on MRI-PDFF
Time Frame: Assessed for up to approximately 20 weeks
|
Assessed for up to approximately 20 weeks
|
Proportion of patients experiencing a relative reduction of 30% or greater of liver fat as assessed by MRI-PDFF
Time Frame: Assessed for up to approximately 20 weeks
|
Assessed for up to approximately 20 weeks
|
Assess the PD effect of FT-4101 on circulation biomarkers of liver inflammation after administration of multiple doses by assessment of the reduction of the following liver biochemistry markers: ALT, AST, γGT, Alkaline phosphatase, Total bilirubin
Time Frame: Participants to be followed for duration of participation, which is approximately 20 weeks
|
Participants to be followed for duration of participation, which is approximately 20 weeks
|
Maximum concentration (Cmax)
Time Frame: Blood samples for PK analysis collected at up to 9 study visits over the course of approximately 20 weeks
|
Blood samples for PK analysis collected at up to 9 study visits over the course of approximately 20 weeks
|
Time to maximum concentration (Tmax)
Time Frame: Blood samples for PK analysis collected at up to 9 study visits over the course of approximately 20 weeks
|
Blood samples for PK analysis collected at up to 9 study visits over the course of approximately 20 weeks
|
Area under the concentration-time curve for a dosing interval (AUCtau)
Time Frame: Blood samples for PK analysis collected at up to 9 study visits over the course of approximately 20 weeks
|
Blood samples for PK analysis collected at up to 9 study visits over the course of approximately 20 weeks
|
Trough plasma concentrations (Ctrough) at steady state
Time Frame: Blood samples for PK analysis collected at up to 9 study visits over the course of approximately 20 weeks
|
Blood samples for PK analysis collected at up to 9 study visits over the course of approximately 20 weeks
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess the PD effect of FT-4101 on the inhibition of fasting hepatic de novo lipogenesis (DNL) after administration of multiple doses by using a 2-week deuterated water labeling protocol
Time Frame: Blood samples for PD analysis collected at up to 11 study visits over the course of approximately 20 weeks
|
Blood samples for PD analysis collected at up to 11 study visits over the course of approximately 20 weeks
|
Total sebum production
Time Frame: Skin surface sebum level measured using Sebumeter at up to 10 study visits over the course of approximately 20 weeks
|
Skin surface sebum level measured using Sebumeter at up to 10 study visits over the course of approximately 20 weeks
|
Concentration of sebum lipids
Time Frame: Sebum lipids measured using Sebutape at up to 5 study visits over the course of approximately 20 weeks
|
Sebum lipids measured using Sebutape at up to 5 study visits over the course of approximately 20 weeks
|
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating biomarkers of liver injury and fibrosis - Enhanced liver fibrosis (ELF) score
Time Frame: Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating biomarkers of liver injury and fibrosis - Cytokeratin-18 fragments
Time Frame: Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating biomarkers of liver injury and fibrosis - FibroSure®
Time Frame: Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating biomarkers of liver injury and fibrosis - PRO-C3
Time Frame: Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating metabolic parameters - Fasting Lipids
Time Frame: Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating metabolic parameters - Gycemic parameters
Time Frame: Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating metabolic parameters - Adiponectin
Time Frame: Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating metabolic parameters - FGF-21
Time Frame: Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Assess the PD effect of FT-4101 after administration of multiple doses by assessment of circulating metabolic parameters - Malonyl carnitine
Time Frame: Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Blood samples for PD analysis collected at up to 4 study visits over the course of approximately 20 weeks
|
Steatosis (CAP) determined by FibroScan®
Time Frame: Assessed at 12 weeks
|
Assessed at 12 weeks
|
Liver stiffness (LSM) determined by FibroScan®
Time Frame: Assessed at 12 weeks
|
Assessed at 12 weeks
|
Imaging parameters (Liver Volume [L], Liver Fat Volume Index [L]) assessed by MRI-PDFF
Time Frame: Imaging parameters assessed at up to 3 study visits over the course of approximately 20 weeks
|
Imaging parameters assessed at up to 3 study visits over the course of approximately 20 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Patrick Kelly, MD, Forma Therapeutics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 17, 2019
Primary Completion (ACTUAL)
January 20, 2020
Study Completion (ACTUAL)
January 20, 2020
Study Registration Dates
First Submitted
June 10, 2019
First Submitted That Met QC Criteria
June 27, 2019
First Posted (ACTUAL)
July 2, 2019
Study Record Updates
Last Update Posted (ACTUAL)
March 16, 2022
Last Update Submitted That Met QC Criteria
March 14, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4101-MET-201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonalcoholic Steatohepatitis (NASH)
-
Milton S. Hershey Medical CenterRecruitingExercise | NASH - Nonalcoholic Steatohepatitis | NASH | LiverUnited States
-
Milton S. Hershey Medical CenterNot yet recruitingLiver Diseases | NASH - Nonalcoholic Steatohepatitis | NASH
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingFibrosis | Cirrhosis | NAFLD | NASH - Nonalcoholic Steatohepatitis | NASH
-
Guangdong Raynovent Biotech Co., LtdRecruitingNonalcoholic Steatohepatitis (NASH)China
-
Massachusetts General HospitalRecruitingNASH - Nonalcoholic SteatohepatitisUnited States
-
Lipocine Inc.CompletedNonalcoholic Steatohepatitis (NASH)United States
-
Akero Therapeutics, IncActive, not recruitingNASH - Nonalcoholic SteatohepatitisUnited States, Puerto Rico
-
CytoDyn, Inc.Amarex Clinical ResearchCompletedNonalcoholic Steatohepatitis (NASH)United States
-
Sinew Pharma Inc.TerminatedNASH - Nonalcoholic SteatohepatitisTaiwan
-
Meridian Bioscience, Inc.Bristol-Myers SquibbCompletedNASH - Nonalcoholic SteatohepatitisUnited States
Clinical Trials on FT-4101
-
Axonics, Inc.RecruitingUrinary Urge Incontinence (UUI) | Fecal Incontinence (FI) | Urinary Frequency (UF)Netherlands, United States
-
Gravitas Medical, Inc.Recruiting
-
Frontera TherapeuticsRecruitingBiallelic RPE65 Mutation-associated Retinal DystrophyChina
-
Tactile MedicalTerminatedBreast Cancer Related LymphedemaUnited States
-
Forma Therapeutics, Inc.Emory UniversityNot yet recruitingSickle Cell DiseaseUnited States
-
Bloom TechnologiesRecruitingFetal MonitoringBelgium
-
Taiho Oncology, Inc.Completed
-
Frontera TherapeuticsPeking Union Medical College Hospital; The First Affiliated Hospital of Zhengzhou... and other collaboratorsRecruiting
-
Frontera TherapeuticsPeking Union Medical College Hospital; Eye & ENT Hospital of Fudan University; Henan Provincial People's HospitalRecruitingX-Linked Retinitis PigmentosaChina
-
Frontera TherapeuticsPeking Union Medical College Hospital; The First Affiliated Hospital of Soochow... and other collaboratorsNot yet recruitingNeovascular Age-related Macular Degeneration